STAT+: What’s the deal with Isomorphic Labs?
Reported by STAT News · all stories from statnews.com
Editorial digest
An analysis from STAT News explores the trajectory and business strategy of Isomorphic Labs. The piece reviews how the computational drug design venture is progressing within the biopharma landscape.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at STAT News →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom11/4/2026
STAT+: The biotech startups skipping AI for drug discovery
Some emerging biotechnology firms are choosing to bypass artificial intelligence tools when developing new pharmaceuticals.
- Trusted health newsroom11/10/2026
STAT+: Oura to acquire Counsel Health for $625 million, placing a big bet on AI care
Oura plans to purchase Counsel Health in a $625 million deal focused on artificial intelligence healthcare services.
- Trusted health newsroom10/28/2026
STAT+: Why every health care AI company must face Epic
A report examines why developers of medical artificial intelligence must inevitably contend with electronic health record giant Epic.
- Trusted health newsroom10/28/2026
STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technology
Epic Systems' expanding market influence is reportedly stifling technological innovation across the healthcare sector.
- Trusted health newsroom10/14/2026
STAT+: The startup chasing ‘general biological intelligence’
A new company is pursuing advanced biological AI capabilities.
- Trusted health newsroom10/23/2026
STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
Pathos has secured $237 million in financing, elevating the artificial intelligence drugmaker's estimated value to $3 billion.